NL-OMON36034已完成2 期
An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals' candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination in healthy subjects aged 60 years of age and older. - ZOSTER-024
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g. return for follow-up visits)
- •2) Previous participation in study ZOSTER-003 as a member of the 50µg gE/AS01B vaccine group
- •3) Written informed consent obtained from the subject.
排除标准
- •1) Having participated in another study at any time after ZOSTER-003 study end in which the subject was exposed to an investigational or non-investigational product (pharmaceutical product or device) or; concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device)
- •2) Administration of immunoglobulins and/or any blood products within the 3 months preceding the first blood draw
- •3) Having received a vaccine containing 3-O-desacyl-4*-Monophosphoryl Lipid A (MPL) and/or Quillaja saponaria Molina, fraction 21 (QS21), any time after ZOSTER-003 study end
- •4) Having received a vaccine against HZ any time after ZOSTER-003 study end
- •5) Subject who did not receive a complete vaccination course of 2 doses of 50µg gE/AS01B in study ZOSTER-003
研究者
相似试验
进行中（未招募）
不适用
ong term immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine 1437173A in healthy subjectsEvaluation of persistence of immune responses following immunisation of healthy elderly subjects (60-69 and =70 years) against Herpes Zoster (HZ)MedDRA version: 14.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-022248-19-CZGlaxoSmithKline Biologicals166
进行中（未招募）
不适用
An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination in healthy subjects aged 60 years of age and older. - ZOSTER-024EUCTR2010-022248-19-SEGlaxoSmithKline Biologicals167
进行中（未招募）
不适用
An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination in healthy subjects aged 60 years of age and older. - ZOSTER-024Evaluation of persistence of immune responses following immunisation of healthy elderly subjects (60-69 and =70 years) against Herpes Zoster (HZ)MedDRA version: 15.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-022248-19-DEGlaxoSmithKline Biologicals166
进行中（未招募）
1 期
An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination in healthy subjects aged 60 years of age and older. - ZOSTER-024EUCTR2010-022248-19-NLGlaxoSmithKline Biologicals166
进行中（未招募）
1 期
Study to evaluate immunogenicity and safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine at 9 and 10 years after vaccine administration and assessment of re-vaccination with 2 additional doses at 10 years after initial vaccination, in healthy subjects aged 60 years of age and older.Herpes Zoster (HZ)MedDRA version: 18.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLGTClassification code 10047438Term: Viral infectious disordersSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004400-30-CZGlaxoSmithKline Biologicals SA100